BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 31406218)

  • 1. A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts.
    Lázaro-Gorines R; Ruiz-de-la-Herrán J; Navarro R; Sanz L; Álvarez-Vallina L; Martínez-Del-Pozo A; Gavilanes JG; Lacadena J
    Sci Rep; 2019 Aug; 9(1):11680. PubMed ID: 31406218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production and characterization of a colon cancer-specific immunotoxin based on the fungal ribotoxin α-sarcin.
    Carreras-Sangrà N; Tomé-Amat J; García-Ortega L; Batt CA; Oñaderra M; Martínez-del-Pozo A; Gavilanes JG; Lacadena J
    Protein Eng Des Sel; 2012 Aug; 25(8):425-35. PubMed ID: 22718791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties.
    Pirie CM; Hackel BJ; Rosenblum MG; Wittrup KD
    J Biol Chem; 2011 Feb; 286(6):4165-72. PubMed ID: 21138845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inclusion of a Furin Cleavage Site Enhances Antitumor Efficacy against Colorectal Cancer Cells of Ribotoxin α-Sarcin- or RNase T1-Based Immunotoxins.
    Ruiz-de-la-Herrán J; Tomé-Amat J; Lázaro-Gorines R; Gavilanes JG; Lacadena J
    Toxins (Basel); 2019 Oct; 11(10):. PubMed ID: 31614771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies.
    Mikkelsen K; Harwood SL; Compte M; Merino N; Mølgaard K; Lykkemark S; Alvarez-Mendez A; Blanco FJ; Álvarez-Vallina L
    Front Immunol; 2019; 10():1791. PubMed ID: 31417564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion.
    Park S; Nguyen MQ; Ta HKK; Nguyen MT; Lee G; Kim CJ; Jang YJ; Choe H
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
    Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
    Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
    Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
    Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
    Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immuno-PET Imaging and Pharmacokinetics of an Anti-CEA scFv-based Trimerbody and Its Monomeric Counterpart in Human Gastric Carcinoma-Bearing Mice.
    Rios X; Compte M; Gómez-Vallejo V; Cossío U; Baz Z; Morcillo MÁ; Ramos-Cabrer P; Alvarez-Vallina L; Llop J
    Mol Pharm; 2019 Mar; 16(3):1025-1035. PubMed ID: 30726099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel recombinant anti-HER2/neu immunotoxin: design and antitumor efficiency.
    Sokolova EA; Zdobnova TA; Stremovskiy OA; Balalaeva IV; Deyev SM
    Biochemistry (Mosc); 2014 Dec; 79(12):1376-81. PubMed ID: 25716732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
    Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
    Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
    Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
    Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.
    Cao Y; Marks JD; Huang Q; Rudnick SI; Xiong C; Hittelman WN; Wen X; Marks JW; Cheung LH; Boland K; Li C; Adams GP; Rosenblum MG
    Mol Cancer Ther; 2012 Jan; 11(1):143-53. PubMed ID: 22090420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanobody-Based EGFR-Targeting Immunotoxins for Colorectal Cancer Treatment.
    Narbona J; Hernández-Baraza L; Gordo RG; Sanz L; Lacadena J
    Biomolecules; 2023 Jun; 13(7):. PubMed ID: 37509078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation of a novel EGFR specific immunotoxin and its efficacy of anti-colorectal cancer in vitro and in vivo.
    Wu S; Deng C; Zhang C; Xiong J; Gu X; Wang Z; Tu J; Xie J
    Clin Transl Oncol; 2021 Aug; 23(8):1549-1560. PubMed ID: 33474678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin.
    Zhou X; Qiu J; Wang Z; Huang N; Li X; Li Q; Zhang Y; Zhao C; Luo C; Zhang N; Teng X; Chen Z; Liu X; Yu X; Wu W; Wei YQ; Li J
    J Cancer Res Clin Oncol; 2012 Jul; 138(7):1081-90. PubMed ID: 22392077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator.
    Xiang Y; Li Q; Huang D; Tang X; Wang L; Shi Y; Zhang W; Yang T; Xiao C; Wang J
    Exp Biol Med (Maywood); 2015 Feb; 240(2):160-8. PubMed ID: 25125500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production of a Granulysin-Based, Tn-Targeted Cytolytic Immunotoxin Using Pulsed Electric Field Technology.
    Guerrero-Ochoa P; Aguilar-Machado D; Ibáñez-Pérez R; Macías-León J; Hurtado-Guerrero R; Raso J; Anel A
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32859066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection and characterization of human anti-MAGE-A1 scFv and immunotoxin.
    Lin H; Mao Y; Zhang DW; Li H; Qiu JR; Zhu J; Chen RJ
    Anticancer Agents Med Chem; 2013 Oct; 13(8):1259-66. PubMed ID: 23343082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.